恒瑞医药(01276.HK)：北京盛迪“SHR-2906注射液”获药物临床试验批准

Group 1 - The core point of the article is that Jiangsu Hengrui Medicine Co., Ltd.'s subsidiary, Beijing Shengdi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of SHR-2906 injection, which will soon commence [1][2] Group 2 - Drug Name: SHR-2906 Injection [2] - Dosage Form: Injection [2] - Application Matter: Clinical Trial [2] - Acceptance Number: CXSL2500799 [2] - Approval Conclusion: The clinical trial application for SHR-2906 injection, accepted on September 17, 2025, meets the requirements for drug registration and is approved to conduct clinical trials for overweight or obesity [2]